LC
CYTK icon

Lindbrook Capital’s Cytokinetics CYTK Stock Holding History

Lindbrook Capital’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$19.2K Buy
478
+194
+68% +$8.92K ﹤0.01% 1370
2024
Q4 		$13.4K Sell
284
-178
-39% -$9.24K ﹤0.01% 1496
2024
Q3 		$24.4K Buy
462
+135
+41% +$7.53K ﹤0.01% 1188
2024
Q2 		$17.7K Buy
327
+129
+65% +$7.79K ﹤0.01% 1314
2024
Q1 		$13.9K Buy
198
+8
+4% +$619 ﹤0.01% 1390
2023
Q4 		$15.9K Sell
190
-107
-36% -$3.88K ﹤0.01% 1310
2023
Q3 		$8.75K Sell
297
-11
-4% -$366 ﹤0.01% 1482
2023
Q2 		$10K Buy
308
+50
+19% +$1.85K ﹤0.01% 1465
2023
Q1 		$9.08K Sell
258
-173
-40% -$7.06K ﹤0.01% 1507
2022
Q4 		$19.7K Sell
431
-167
-28% -$7.19K ﹤0.01% 1069
2022
Q3 		$29K Buy
598
+110
+23% +$5.29K ﹤0.01% 825
2022
Q2 		$19K Buy
488
+56
+13% +$2.25K ﹤0.01% 983
2022
Q1 		$16K Buy
432
+282
+188% +$10K ﹤0.01% 1093
2021
Q4 		$7K Buy
150
+100
+200% +$3.86K ﹤0.01% 1394
2021
Q3 		$2K Buy
+50
New +$1.47K ﹤0.01% 1520

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Lindbrook Capital's CYTK Position: Q1 2025 in Review

Lindbrook Capital increased its Cytokinetics (CYTK) stake by 68% in Q1 2025, buying an estimated $8.92K and bringing the position to 478 shares worth $19.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1370.

Lindbrook Capital first reported a position in CYTK in Q3 2021 and has held it in 15 quarters since. The position peaked at $29K in Q3 2022. 355 funds tracked by Wall St. Rank hold CYTK as of Q1 2025.

  • Lindbrook Capital held 478 shares of Cytokinetics worth $19.2K as of Q1 2025.
  • Lindbrook Capital bought 194 Cytokinetics shares in Q1 2025, an estimated $8.92K.
  • Cytokinetics made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1370 holding.
  • Lindbrook Capital first reported a position in Cytokinetics in Q3 2021 and has held it in 15 quarters since.
  • Lindbrook Capital's Cytokinetics position peaked at $29K in Q3 2022.
  • 355 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.